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Body fat distribution is a heritable trait and a well-established predictor of adverse metabolic outcomes, independent of
overall adiposity. To increase our understanding of the genetic basis of body fat distribution and its molecular links to
cardiometabolic traits, here we conduct genome-wide association meta-analyses of traits related to waist and hip cir-
cumferences in up to 224,459 individuals. We identify 49 loci (33 new) associated with waist-to-hip ratio adjusted for
body mass index (BMI), and an additional 19 loci newly associated with related waist and hip circumference measures
(P,53 1028). In total, 20of the49waist-to-hip ratioadjusted forBMI loci showsignificant sexualdimorphism, 19ofwhich
display a stronger effect inwomen. The identified lociwere enriched forgenes expressed in adipose tissue and for putative
regulatoryelements inadipocytes.Pathwayanalyses implicatedadipogenesis, angiogenesis, transcriptional regulationand
insulin resistance as processes affecting fat distribution, providing insight into potential pathophysiological mechanisms.
Depot-specific accumulationof fat, particularly in the central abdomen,
confers an increased risk ofmetabolic and cardiovascular diseases and
mortality1.Aneasily accessiblemeasure of body fat distribution iswaist-
to-hip ratio (WHR), a comparison of waist and hip circumferences. A
largerWHR indicatesmore intra-abdominal fat depositionand is asso-
ciated with higher risk for type 2 diabetes (T2D) and cardiovascular
disease2,3. Conversely, a smallerWHRindicates greater gluteal fat accu-
mulation and is associated with lower risk for T2D, hypertension, dys-
lipidemia andmortality4–6.Ourprevious genome-wide association study
(GWAS)meta-analyses have identified loci forWHRafter adjusting for
body mass index (WHRadjBMI)7,8. These loci are enriched for asso-
ciation with other metabolic traits7,8 and show that different fat distri-
bution patterns can have distinct genetic components9,10.
To determine further the genetic architecture of fat distribution and
to increase our understanding of molecular connections with cardio-
metabolic traits, we performed ameta-analysis ofWHRadjBMI associ-
ations in 142,762 individuals with GWAS data and 81,697 individuals
genotypedwith theMetabochip11, all from theGenetic Investigation of
ANthropometric Traits (GIANT) consortium. Given the marked sex-
ual dimorphism previously observed among establishedWHRadjBMI
loci7,8, weperformedanalyses inmenandwomen separately, the results
ofwhichwere subsequently combined.To characterize the geneticdeter-
minants of specific aspects of body fat distribution more fully, we
performed secondary GWAS meta-analyses for five additional traits:
unadjustedWHR, unadjustedwaist circumference, BMI-adjustedwaist
circumference (WCadjBMI), unadjusted hip circumference and BMI-
adjusted hip circumference (HIPadjBMI).We evaluated the associated
loci to understand their contributions to variation in fat distribution
and adipose tissue biology, and their molecular links to cardiometa-
bolic traits.
New loci associated with WHRadjBMI
We performed meta-analyses of GWAS of WHRadjBMI in up to
142,762 individuals of European ancestry from 57 new or previously
described GWAS7, and separately in up to an additional 67,326 Euro-
pean ancestry individuals from 44Metabochip studies (ExtendedData
Fig. 1 and Supplementary Tables 1–3). The combination of these two
meta-analyses included up to 2,542,447 autosomal single nucleotide
polymorphisms (SNPs) inup to210,088Europeanancestry individuals.
We defined new loci based on genome-wide significant association
(P, 53 1028 after genomic control correction at both the study-specific
andmeta-analytic levels) and distance (.500 kilobases (kb) from pre-
viously established loci)7,8.
We identified 49 loci for WHRadjBMI, 33 of which were new and
16previously described7,8. Of these, a European ancestry sex-combined
analysis identified 39 loci, 24ofwhichwerenew7,8 (Table 1, Supplemen-
tary Table 4 and Supplementary Figs 1–3). European ancestry sex-
specific analyses identified nine additional loci, eight of which were
new and significant in women but not inmen (all Pmen. 0.05; Table 1
and Supplementary Fig. 4). The addition of 14,371 individuals of non-
European ancestry genotyped on theMetabochip identified one addi-
tional locus in women (rs1534696, near SNX10, Pwomen 5 2.13 10
28,
Pmen 5 0.26, Table 1 and Supplementary Tables 1–3), with no evidence
of heterogeneity across ancestries (Phet5 0.86; Supplementary Note).
Genetic architecture of WHRadjBMI
To evaluate sexual dimorphism, we compared sex-specific effect size
estimates of the 49WHRadjBMI lead SNPs. The effect estimates were
significantly different (Pdifference, 0.05/495 0.001) at 20 SNPs, 19 of
which showed larger effects in women (Table 1 and Extended Data
Fig. 2a), similar to previous findings7,8. The only SNP that showed a
larger effect in men mapped near GDF5 (rs224333, bmen 5 0.036 and
P5 9.03 10212,bwomen5 0.009 andP5 0.074,Pdifference5 6.4310
25),
a locus previously associated with height (rs6060369, r2 5 0.96 and
rs143384, r2 5 0.96, 1000 Genomes Project CEU), although without
significant differences between sexes12,13. Consistent with the larger
number of loci identified inwomen, variance component analyses dem-
onstrated a significantly larger heritability (h2) of WHRadjBMI in
women than men in the Framingham Heart Study (h2women5 0.46,
h2men 5 0.19,Pdifference5 0.0037) andTwinGene study (h
2
women 5 0.56,
h2men 5 0.32, Pdifference5 0.001; Supplementary Table 5 and Extended
Data Fig. 2b).
To identifymultiple association signalswithin observed loci, we per-
formed approximate conditional analyses of the sex-combined and
sex-specific summary statistics using GCTA14 (Supplementary Note).
Several signals (P, 53 1028) were identified at nine loci (Extended
Data Table 1). Fitting SNPs jointly identified different lead SNPs in the
sex-specific and sex-combined analyses. For example, the MAP3K1-
ANKRD55 locus showed near-independent (linkage disequilibrium
(LD) r2, 0.01) SNPs 54 kb apart that were significant only in women
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(rs3936510) or only in men (rs459193; Extended Data Table 1, Sup-
plementary Table 4). Other signals are more complex. The TBX15-
WARS2 locus showed different but correlated lead SNPs in men and
women nearWARS2 (r2 5 0.43), an independent signal near TBX15,
and a distant independent signal near SPAG17 (Fig. 1). At theHOXC
gene cluster, conditional analyses identified independent (r2, 0.01)
SNPs,80kbapartnearHOXC12-HOXC13-HOTAIRandnearHOXC4-
HOXC6 (Fig. 1). These results suggest that association signalsmapping
to the same locusmight act on different underlying genes andmay not
be relevant to the same sex.
We assessed the aggregate effects of the primary association signals
at the49WHRadjBMI loci by calculating sex-combined and sex-specific
risk based on genotypes of the lead SNPs. In a linear regressionmodel,
the risk scoreswere associatedwithWHRadjBMI,with a stronger effect
inwomen than inmen (overall effect per alleleb5 0.001,P5 6.73 1024,
women b5 0.002, P5 1.03 10211, men b5 7.03 1024, P5 0.02;
Table 1 | WHRadjBMI loci in sex-combined and sex-specific meta-analyses
Sex-combined Women Men Sex diff.
SNP Chr Locus EA* EAF b P N b P N b P N P{
Novel loci achieving genome-wide significance in European-ancestry meta-analyses
rs905938 1 DCST2 T 0.74 0.025 7.3310210 207,867 0.034 4.9310210 115,536 0.015 1.131022 92,461 1.631022
rs10919388 1 GORAB C 0.72 0.024 3.231029 181,049 0.033 4.8310210 102,446 0.013 3.031022 78,738 9.831023
rs1385167 2 MEIS1 G 0.15 0.029 1.931029 206,619 0.023 4.031024 114,668 0.036 2.331027 92,085 1.631021
rs1569135 2 CALCRL A 0.53 0.021 5.6310210 209,906 0.023 6.931027 116,642 0.019 1.531024 93,398 5.831021
rs10804591 3 PLXND1 A 0.79 0.025 6.631029 209,921 0.040 6.1310213 116,667 0.004 5.331021 93,387 5.731026
rs17451107 3 LEKR1 T 0.61 0.026 1.1310212 207,795 0.023 1.031026 115,735 0.030 1.431028 92,194 3.531021
rs3805389 4 NMU A 0.28 0.012 1.531023 209,218 0.027 4.631028 116,226 20.007 2.131021 93,125 1.631026
rs9991328 4 FAM13A T 0.49 0.019 4.531028 209,925 0.028 3.4310210 116,652 0.007 1.731021 93,407 8.531024
rs303084 4 SPATA5-
FGF2
A 0.80 0.023 3.931028 209,941 0.029 3.431027 116,662 0.016 9.931023 93,412 1.131021
rs9687846 5 MAP3K1 A 0.19 0.024 7.131028 208,181 0.041 3.8310212 115,897 0.000 9.731021 92,417 1.331026
rs6556301 5 FGFR4 T 0.36 0.022 2.631028 178,874 0.018 7.131024 101,638 0.029 1.031026 77,370 1.431021
rs7759742 6 BTNL2 A 0.51 0.023 4.4310211 208,263 0.024 1.731027 115,648 0.023 5.531026 92,749 8.631021
rs1776897 6 HMGA1 G 0.08 0.030 1.131025 177,879 0.052 6.831029 100,516 0.003 7.431021 77,497 1.831024
rs7801581 7 HOXA11 T 0.24 0.027 3.7310210 195,215 0.025 7.731026 108,866 0.029 2.431026 86,483 6.931021
rs7830933 8 NKX2-6 A 0.77 0.022 7.431028 209,766 0.037 1.2310212 116,567 0.001 8.431021 93,333 1.431026
rs12679556 8 MSC G 0.25 0.027 2.1310211 203,826 0.033 2.1310210 114,369 0.017 4.231023 89,591 2.831022
rs10991437 9 ABCA1 A 0.11 0.031 1.031028 209,941 0.040 2.831028 116,644 0.022 6.131023 93,430 7.231022
rs7917772 10 SFXN2 A 0.62 0.014 5.631025 209,642 0.027 5.531029 116,514 20.001 8.631021 93,263 2.331025
rs11231693 11 MACROD1-
VEGFB
A 0.06 0.041 4.531028 198,072 0.068 2.7310211 110,164 0.009 4.231021 88,043 2.531025
rs4765219 12 CCDC92 C 0.67 0.028 1.6310215 209,807 0.037 1.0310214 116,592 0.018 5.331024 93,350 5.731023
rs8042543 15 KLF13 C 0.78 0.026 1.231029 208,255 0.023 6.731025 115,760 0.030 1.031026 92,629 3.631021
rs8030605 15 RFX7 A 0.14 0.030 8.831029 208,374 0.031 1.031025 115,864 0.031 5.931025 92,644 9.931021
rs1440372 15 SMAD6 C 0.71 0.024 1.1310210 207,447 0.022 1.131025 115,201 0.027 1.431026 92,380 5.231021
rs2925979 16 CMIP T 0.31 0.018 1.231026 207,828 0.032 3.4310211 115,431 20.002 7.931021 92,531 1.231026
rs4646404 17 PEMT G 0.67 0.027 1.4310211 198,196 0.034 5.3310211 115,337 0.017 2.531023 87,857 2.631022
rs8066985 17 KCNJ2 A 0.50 0.018 1.431027 209,977 0.026 4.031029 116,683 0.007 1.931021 93,428 1.831023
rs12454712 18 BCL2 T 0.61 0.016 1.031024 169,793 0.035 1.131029 96,182 20.007 2.531021 73,576 1.631027
rs12608504 19 JUND A 0.36 0.022 8.8310210 209,990 0.017 2.631024 116,689 0.028 1.131027 93,435 1.231021
rs4081724 19 CEBPA G 0.85 0.035 7.4310212 207,418 0.033 9.231027 115,322 0.039 1.431027 92,230 5.031021
rs979012 20 BMP2 T 0.34 0.027 3.3310214 209,941 0.026 1.031027 116,668 0.028 6.631028 93,407 6.731021
rs224333 20 GDF5 G 0.62 0.020 2.631028 208,025 0.009 7.431022 115,803 0.036 9.0310212 92,356 6.431025
rs6090583 20 EYA2 A 0.48 0.022 6.2310211 209,435 0.029 2.8310210 116,382 0.015 2.431023 93,187 3.231022
Novel loci achieving genome-wide significance in all-ancestry meta-analyses
rs1534696 7 SNX10 C 0.43 0.011 1.331023 212,501 0.027 2.131028 118,187 20.006 2.631021 92,243 2.131026
Previously reported loci achieving genome-wide significance in European-ancestry meta-analyses
rs2645294 1 TBX15-
WARS2
T 0.58 0.031 1.7310219 209,808 0.035 1.5310214 116,596 0.027 1.531027 93,346 2.031021
rs714515 1 DNM3-
PIGC
G 0.43 0.027 4.4310215 203,401 0.029 1.8310210 113,939 0.025 8.531027 89,596 5.131021
rs2820443 1 LYPLAL1 T 0.72 0.035 5.3310221 209,975 0.062 5.7310235 116,672 0.002 6.931021 93,437 2.6310217
rs10195252 2 GRB14-
COBLL1
T 0.59 0.027 5.9310215 209,395 0.052 4.7310230 116,329 20.003 5.331021 93,199 2.4310217
rs17819328 3 PPARG G 0.43 0.021 2.431029 208,809 0.035 4.6310214 116,072 0.005 3.331021 92,871 5.131026
rs2276824 3 PBRM1{ C 0.43 0.024 3.2310211 208,901 0.028 3.731029 116,128 0.020 1.431024 92,907 2.031021
rs2371767 3 ADAMTS9 G 0.72 0.036 1.6310220 194,506 0.056 1.2310226 108,624 0.012 3.531022 86,016 3.631029
rs1045241 5 TNFAIP8-
HSD17B4
C 0.71 0.019 4.431027 209,710 0.035 6.6310212 116,560 20.001 9.331021 93,284 8.331027
rs7705502 5 CPEB4 A 0.33 0.027 4.7310214 209,827 0.027 1.931028 116,609 0.027 2.331027 93,352 .0.99
rs1294410 6 LY86 C 0.63 0.031 2.0310218 209,830 0.037 1.6310215 116,624 0.025 1.431026 93,340 6.331022
rs1358980 6 VEGFA T 0.47 0.039 3.1310227 206,862 0.060 3.7310234 115,047 0.015 4.031023 91,949 3.7310211
rs1936805 6 RSPO3 T 0.51 0.043 3.6310235 209,859 0.052 3.7310230 116,602 0.031 3.1310210 93,392 1.031023
rs10245353 7 NFE2L3 A 0.20 0.035 8.4310216 210,008 0.041 7.9310213 116,704 0.027 1.431025 93,438 7.231022
rs10842707 12 ITPR2-
SSPN
T 0.23 0.032 4.4310216 210,023 0.041 6.1310215 116,704 0.022 1.431024 93,453 1.131022
rs1443512 12 HOXC13 A 0.24 0.028 6.9310213 209,980 0.040 1.1310214 116,688 0.013 2.831022 93,425 1.631024
rs2294239 22 ZNRF3 A 0.59 0.025 7.2310213 209,454 0.028 6.9310210 116,414 0.024 2.331026 93,173 5.031021
Loci achieving genome-wide significance (P,5 31028) in sex-combined and/or sex-specific meta-analyses. P values and b coefficients for the association with WHRadjBMI in the meta-analyses of combined
GWAS and Metabochip studies. The smallest P value for each SNP is shown in bold. Chr, chromosome; EAF, effect allele frequency.
*The effect allele (EA) is the WHRadjBMI-increasing allele in the sex-combined analysis.
{Test for sex difference; values significant at the table-wise Bonferroni threshold of 0.05/4951.02 31023 are marked in bold.
{Locus previously named NISCH-STAB1. Additional analyses that showed no significant evidence of heterogeneity between studies or due to ascertainment are provided in Supplementary Tables 27 and 28
(Supplementary Note).
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ExtendedDataFig. 3 and SupplementaryNote).The 49SNPs explained
1.4%of the variance inWHRadjBMIoverall, andmore inwomen (2.4%)
than in men (0.8%) (Supplementary Table 6). Compared to the 16
previously reported loci7,8, the new loci almost doubled the explained
variance in women and tripled that in men.We further estimated that
the sex-combined variance explained by all HapMap SNPs15 (h2G) is
12.1% (s.e.m. 5 2.9%).
At 17 loci with high-density coverage on theMetabochip11, we used
association summary statistics to define credible sets of SNPswith ahigh
probability of containing a likely functional variant. The 99% credible
sets at seven loci spanned,20kb, and atHOXC13 includedonly a single
noncoding SNP (Supplementary Table 7 and Supplementary Fig. 5).
Imputation up to higher density reference panels will provide greater
coverage and may have more potential to localize functional variants.
WHRadjBMI variants and other traits
Given the epidemiological correlations between central obesity and
other anthropometric and cardiometabolic measures and diseases, we
evaluated leadWHRadjBMI variants in association data from GWAS
consortia for 22 traits. In total, 17 of the 49 variants were associated
(P, 53 1028) with at least one of the traits: high-density lipoprotein
cholesterol (HDL; n5 7 SNPs), triglycerides (n5 5), low-density lipo-
protein cholesterol (LDL;n5 2), adiponectin adjusted for BMI (n5 3),
fasting insulin adjusted forBMI (n5 2),T2D(n5 1), andheight (n5 7)
(Supplementary Tables 8 and 9). WHRadjBMI SNPs also showed
enrichment for directional consistency among nominally significant
(P, 0.05) associations with these traits and also with fasting and 2-h
glucose, diastolic and systolic bloodpressure, BMI and coronary artery
disease (CAD) (Pbinomial, 0.05/235 0.0022; Extended Data Table 2);
these results were generally supported by meta-regression analysis of
the regression coefficient estimates (SupplementaryTable 10). Further-
more, our WHRadjBMI loci overlap with associations reported in the
National Human Genome Research Institute (NHGRI) GWAS cata-
logue (Table 2 and SupplementaryTable 11)16, the strongest ofwhich is
the locus near LEKR1, which is associated (P5 2.03 10235) with birth
weight17. Unsupervised hierarchical clustering of the corresponding
matrix of association Z-scores showed three major clusters character-
ized by patterns of anthropometric and metabolic traits (Extended
Data Fig. 4). These data extend knowledge about genetic links between
WHRadjBMI and insulin-resistance-related traits; whether this reflects
underlying causal relations between WHRadjBMI and these traits, or
pleiotropic loci, cannot be inferred from our data.
Potential functional WHRadjBMI variants
We next examined variants in LD with the WHRadjBMI lead SNPs
(r2. 0.7) for predicted effects on protein sequence, copy number, and
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Figure 1 | Regional SNP association plots
illustrating the complex genetic architecture at
two WHRadjBMI loci. a, b, Sex-combined
meta-analysis SNP associations in European
individuals were plotted with –log10 P values
(left y axis) and estimated local recombination rate
in blue (right y axis). Three index SNPs near
HOXC6-HOXC13 (denotedA–C) (a) and four near
TBX15-WARS2-SPAG17 (D–G) (b) were identified
through approximate conditional analyses of
sex-combined or sex-specific associations (values
shown as Pconditional, 53 10
28, see Methods).
The signals are distinguished by both colour and
shape, and linkage disequilibrium (r2) of nearby
SNPs is shown by colour intensity gradient. Sample
sizes for the index SNP associations are listed in
Extended Data Table 1.
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cis-regulatory effects on expression (Table 2, SupplementaryTables 12–15
andSupplementaryNote).At 11of thenew loci, leadWHRadjBMISNPs
were in LDwith cis-expression quantitative trait loci (eQTLs) for tran-
scripts in subcutaneous adipose tissue, omental adipose tissue, liver or
blood cell types (Table 2 and Supplementary Table 15). No additional
sex-specific eQTLs were identified, perhaps reflecting limited power
(Supplementary Table 16).
At the 11 WHRadjBMI loci containing eQTLs, we compared the
location of the candidate variants to regions of open chromatin (DNase
I hypersensitivity and formaldehyde-assisted isolationof regulatory ele-
ments (FAIRE)) and histone modification enrichment (histone 3 Lys 4
methylation (H3K4me1),H3K4me2,H3K4me3, histone 3Lys 27 acety-
lation (H3K27ac), andH3K9ac) in adipose, liver, skeletalmuscle, bone,
brain, blood and pancreatic islet tissues or cell lines (Supplementary
Table 17).At 7 of these 11 loci, at least one variantwas located in aputa-
tive regulatory element in two ormore data sets from the same tissue as
the eQTL, suggesting that these elementsmay influence transcriptional
activity (SupplementaryTable 18). For example, atLEKR1, five variants
in LD with the WHRadjBMI lead SNP are located in a 1.1-kb region
with evidence of enhancer activity (H3K4me1 and H3K27ac) in adi-
pose tissue (Extended Data Fig. 5a).
We also examinedwhether any variants overlappedwith open chro-
matin or histone modifications from only one of the tested tissues,
possibly reflecting tissue-specific regulatory elements (Supplementary
Table 18). For example, five variants in a 2.2-kb region, located 77 kb
upstreamfromaCALCRL transcription start site, overlappedwithpeaks
in at least five data sets in endothelial cells (Extended Data Fig. 5b),
suggesting that one or more of these variants may influence transcrip-
tional activity.CALCRL,which is expressed in endothelial cells, is required
for lipid absorption in the small intestine, and influences body weight
inmice18. Other variants located in tissue-specific regulatory elements
were detected at NMU for endothelial cells, at KLF13 andMEIS1 for
liver, and at GORAB andMSC for bone (Supplementary Table 18).
Biological mechanisms
To identify potential functional connections between genes mapping
to the 49 WHRadjBMI loci, we used three approaches (Supplemen-
taryNote). A surveyof literatureusingGRAIL19 identified 15 geneswith
nominal significance (P, 0.05) for potential functional connectivity
(Table 2 and Supplementary Table 19). The predefined gene set rela-
tionships across loci identified usingMAGENTA20 highlighted signal-
ling pathways involving vascular endothelial growth factor (VEGF),
phosphatase and tensin (PTEN) homologue, the insulin receptor, and
peroxisomeproliferator-activated receptors (SupplementaryTable 20).
VEGF signalling plays a central, complex role in angiogenesis, insulin
resistance and obesity21, and PTEN signalling promotes insulin resist-
ance22. Analyses using Data-driven Expression Prioritized Integration
forComplexTraits (DEPICT)23 facilitatedprioritizationof genes at asso-
ciated loci, analyses of tissue specificity, and enrichment of reconsti-
tutedgene sets through integrationof association resultswith expression
data, protein–protein interactions, phenotypic data fromgeneknockout
studies inmice, andpredefined gene sets. DEPICT identified at least one
Table 2 | Candidate genes at new WHRadjBMI loci
SNP Locus eQTL
(P,1025)*
GRAIL
(P,0.05){
DEPICT
(FDR,0.05){
Literature1 Other GWAS signalsI
rs905938 DCST2 ZBTB7B (PB, blood) - - - -
rs10919388 GORAB - - - - -
rs1385167 MEIS1 - - - MEIS1 -
rs1569135 CALCRL - TFPI - CALCRL -
rs10804591 PLXND1 - - PLXND1 -
rs17451107 LEKR1 TIPARP (S,O), LEKR1 (S) - - Birth weight: CCNL1, LEKR1
rs3805389 NMU - - - NMU -
rs9991328 FAM13A FAM13A (S) FAM13A - FI: FAM13A
rs303084 SPATA5-FGF2 - FGF2 - FGF2, NUDT6, SPRY1 -
rs9687846 MAP3K1 - MAP3K1 - MAP3K1 FI, TG: ANKRD55, MAP3K1
rs6556301 FGFR4 - MXD3 - FGFR4 Height
rs7759742 BTNL2 HLA-DRA (S), KLHL31 (S) - (not analysed) - -
rs1776897 HMGA1 - - (not analysed) HMGA1 Height:HMGA1,C6orf106, LBH
rs1534696 SNX10 SNX10 (S), CBX3 (S) - - SNX10 -
rs7801581 HOXA11 - HOXA11 HOXA11 HOXA11 -
rs7830933 NKX2-6 STC1 (S) - - NKX2-6, STC1 -
rs12679556 MSC - EYA1 RP11-1102P16.1 MSC, EYA1 -
rs10991437 ABCA1 - - ABCA1 -
rs7917772 SFXN2 - - - SFXN2 Height
rs11231693 MACROD1-VEGFB - VEGFB MACROD1 MACROD1, VEGFB -
rs4765219 CCDC92 CCDC92 (S, O, L),
ZNF664 (S, O)
FAM101A - - Adiponectin, FI, HDL, TG:
CCDC92, ZNF664
rs8042543 KLF13 - KLF13 - KLF13 -
rs8030605 RFX7 - - - -
rs1440372 SMAD6 SMAD6 (blood) SMAD6 SMAD6 SMAD6 Height
rs2925979 CMIP CMIP (S) - - CMIP, PLCG2 Adiponectin, FI, HDL: CMIP
rs4646404 PEMT - - PEMT PEMT -
rs8066985 KCNJ2 - - - KCNJ2 -
rs12454712 BCL2 - - - BCL2 -
rs12608504 JUND KIAA1683 (PB, O), JUND
(LCL)
JUND - JUND -
rs4081724 CEBPA - CEBPA - CEBPA, CEBPG -
rs979012 BMP2 - BMP2 BMP2 BMP2 Height: BMP2
rs224333 GDF5 CEP250 (S, O), UQCC
(blood, S, O, L, LCL)
GDF5 GDF5 GDF5 Height: GDF5, UQCC
rs6090583 EYA2 - EYA2 EYA2 EYA2 -
Candidate genesbased on secondary analyses or literature review.Details are provided in SupplementaryTables 8, 9, 11–13, 15, 19, 21 andSupplementaryNote. The only non-synonymous variant in high LDwith
an index SNP was GDF5 S276A. No copy number variants were identified. PB, peripheral blood mononuclear cells; FI, fasting insulin adjusted for BMI; HDL, high-density lipoprotein cholesterol; L, liver; LCL,
lymphoblastoid cell line; O, omental adipose; S, subcutaneous adipose; TG, triglycerides.
*Gene transcript levels associated with the SNP in the indicated tissue(s).
{Genes in pathways identified as enriched by GRAIL analysis.
{Significant (FDR,5%) pathway genes derived by DEPICT using GWAS-only results.
1Most plausible candidate genes based on literature review.
ITraits associated at P,5 3 1028 in GWAS or the GWAS catalogue using the index SNP or a proxy, and the genes(s) named.
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prioritized gene (false discovery rate (FDR), 5%) at nine loci (Table 2
and Supplementary Table 21) and identified 234 reconstituted gene
sets (161 after pruning of overlapping gene sets) enriched for genes at
WHRadjBMI loci.Among thesewehighlight biologicallyplausible gene
sets suggesting roles in body fat regulation (including adiponectin sig-
nalling, insulin sensitivity and regulation of glucose levels), skeletal
growth, transcriptional regulation and development (Fig. 2 and Sup-
plementary Table 22).We also note gene sets that are specific for abun-
dance ordevelopmentofmetabolically active tissues including adipose,
heart, liver andmuscle. Specific genesat the lociwere significantly enriched
(FDR, 5%) for expression in adipocyte-related tissues, including abdo-
minal subcutaneous fat (Fig. 2 and SupplementaryTable 23). Together,
these analyses identified processes related to insulin and adipose bio-
logy and highlight mesenchymal tissues, especially adipose tissue, as
important to WHRadjBMI.
We also tested variants at the 49WHRadjBMI loci for overlap with
elements from 60 selected regulatory data sets from the ENCODE24
and Epigenomic RoadMap25 data and found evidence of enrichment
in 12 data sets (P, 0.05/605 8.33 1024; ExtendedData Table 3). The
strongest enrichmentswere detected for data sets typically attributed to
enhancer activity (H3K4me1 andH3K27ac) in adipose, muscle, endo-
thelial cells, andbone, suggesting that variantsmay regulate transcription
in these tissues.Theseanalysespoint tomechanisms linkingWHRadjBMI
loci to regulation of gene expression in tissues highly relevant for adi-
pocyte metabolism and insulin resistance.
We also reviewed functions of candidate genes located near new and
previously establishedWHRadjBMI loci7,8, identifying genes involved
in adipogenesis, angiogenesis and transcriptional regulation (Table 2,
literature review in the Supplementary Note). Adipogenesis candidate
genes includeCEBPA, PPARG, BMP2,HOXC-mir196, SPRY1, TBX15,
andPEMT. Of these,CEBPA andPPARG are essential forwhite adipose
tissue differentiation26, BMP2 induces differentiation ofmesenchymal
stem cells towards adipogenesis or osteogenesis27, and HOXC8 is a
repressor of brown adipogenesis inmice that is regulated bymiR-196a
(ref. 28), also located within the HOXC region (Fig. 1). Angiogenesis
genesmay influence expansion and loss of adipose tissue29; they include
VEGFA, VEGFB, RSPO3, STAB1, WARS2, PLXND1, MEIS1, FGF2,
SMAD6 and CALCRL. VEGFB is involved in endothelial targeting of
lipids to peripheral tissues30, and PLXND1 limits blood vessel branch-
ing, antagonizes VEGF, and affects adipose inflammation31,32. Tran-
scriptional regulators at WHRadjBMI loci include CEBPA, PPARG,
MSC, SMAD6,HOXA,HOXC, ZBTB7B, JUND,KLF13,MEIS1, RFX7,
NKX2-6andHMGA1.Other candidate genes includeNMU,FGFR4 and
HMGA1, for which mice deficient for the corresponding genes exhibit
obesity, glucose intolerance and/or insulin resistance33–35.
Five additional central obesity traits
Todeterminewhether theWHRadjBMI variants exert their effects pri-
marily through waist circumference or hip circumference and to iden-
tify loci that are not reported for WHRadjBMI, BMI or height36,37, we
performed association analyses for five additional traits: WCadjBMI,
HIPadjBMI, WHR, waist circumference and hip circumference. On
the basis of phenotypic data alone,waist circumference andhip circum-
ference are highly correlated with BMI (r5 0.59–0.92), and WHR is
highly correlatedwithWHRadjBMI (r5 0.82–0.95), whileWCadjBMI
and HIPadjBMI are moderately correlated with height (r5 0.24–0.63;
SupplementaryTable 24). In contrast toWHRadjBMI,whichhas almost
no genetic correlation (see Methods) with height (rG, 0.04; Extended
Data Fig. 2c),WCadjBMI (rG 5 0.42) andHIPadjBMI (rG 5 0.82)have
moderategenetic correlationswithheight. Thesedata suggest that some,
but not all, WCadjBMI and HIPadjBMI loci would be associated with
height.
Across all meta-analyses, we identified an additional 19 loci associ-
ated with one of the five traits (P, 53 1028), nine of which showed
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Figure 2 | Gene set enrichment and tissue
expression of genes at WHRadjBMI-associated
loci (GWAS-only P, 1025). a, Reconstituted
gene sets found to be significantly enriched by
DEPICT (FDR, 5%) are represented as nodes,
with pairwise overlap denoted by the width of
connecting lines and empirical enrichment P value
indicated by colour intensity (darker is more
significant). b, The ‘decreased liver weight’
meta-node, which consisted of 12 overlapping gene
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significantly larger effects (Pdifference, 0.05/195 0.003) in one sex than
in the other (Table 3, Supplementary Figs 1–4 and Supplementary
Table 25). Three of four new loci with larger effects in women were
associatedwithHIPadjBMI and three of five new lociwith larger effects
in men were associated with WCadjBMI. Most of the 19 loci showed
some evidence of association with WHRadjBMI in sex-combined or
sex-specific analyses, but four loci showednoassociation (P. 0.01)with
WHRadjBMI, BMI, or height (Supplementary Tables 8 and 26).
We next asked whether the genes and pathways influencing these
five traits are sharedwithWHRadjBMIor are distinct.Candidate genes
were identifiedbasedonassociationwithother traits, eQTLs,GRAILand
literature review (ExtendedData Table 4 and Supplementary Tables 8,
11–13, 15–16 and 19). Candidate variants identified based on LD
(r2. 0.7) included coding variants in NTAN1 and HMGXB4, and six
loci showed significant eQTLs in subcutaneous adipose tissue. On the
basis of the literature, several candidate genes are involved in adi-
pogenesis and insulin resistance. For example, delayed induction of
preadipocyte transcription factor ZNF423 in fibroblasts results in
delayed adipogenesis38, and NLRP3 is part of inflammasome and pro-
inflammatory T-cell populations in adipose tissue that contribute to
inflammation and insulin resistance39. GRAIL analyses identified con-
nections that partially overlap with those identified for WHRadjBMI
(Supplementary Table 19). Taken together, the additional loci appear
to function in processes similar to the WHRadjBMI loci. The iden-
tification of loci that are more strongly associated withWCadjBMI or
HIPadjBMI than the other anthropometric traits suggests that the addi-
tional traits characterize aspects of central obesity and fat distribution
that are not captured by WHRadjBMI or BMI alone.
Discussion
These meta-analyses of GWAS andMetabochip data in up to 224,459
individuals identified additional loci associated with waist and hip cir-
cumferencemeasures and help to determine the role of commongenetic
variation in body fat distribution that is distinct from BMI and height.
Our results emphasize the strong sexual dimorphism in the genetic reg-
ulation of fat distribution traits, a characteristic not observed for overall
obesity as assessedbyBMI36.Differences inbody fat distributionbetween
the sexes emerge in childhood, becomemore apparent during puberty40,
and changewithmenopause, generally attributed to the influence of sex
hormones41,42.At lociwith stronger effects inone sex than theother, these
hormonesmay interactwith transcription factors to regulate gene activity.
Annotation of the loci emphasized the role formesenchymally derived
tissues, especially adipose tissue, in fat distribution and central obesity.
The development and regulation of adipose tissue deposition is closely
associatedwith angiogenesis29, a process highlighted by candidate genes
at several WHRadjBMI loci. These tissues are implicated in insulin
resistance, consistentwith the enrichmentof sharedGWASsignalswith
lipids, T2D, and glycaemic traits. The identification of skeletal growth
processes suggests that the underlying genes affect early development
and/or differentiation of adipocytes from mesenchymal stem cells. By
contrast, BMI has a substantial neuronal component, involving pro-
cesses such as appetite regulation36. Our results provide a foundation
for future biological research in the regulation of body fat distribution
and its connectionswith cardiometabolic traits, andoffer potential target
mechanisms for interventions in the risks associated with abdominal
fat accumulation.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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METHODS
Study overview.Our study included 224,459 individuals of European, east Asian,
southAsian andAfrican-American ancestry. The European ancestry arm included
142,762 individuals from57 cohorts genotypedwith genome-wide SNParrays and
67,326 individuals from 44 cohorts genotyped with the Metabochip11 (Extended
DataFig. 1 andSupplementaryTable 1). Thenon-Europeanancestry armcomprised
,1,700 individuals from one cohort of east Asian ancestry, ,3,400 individuals
fromone cohort of southAsian ancestry, and,9,200 individuals from six cohorts
of African-American ancestry, all genotyped with the Metabochip. There was no
overlap between individuals genotyped with genome-wide SNP arrays andMeta-
bochip. For each study, local institutional committees approved study protocols
and confirmed that informed consent was obtained. No statistical methods were
used to predetermine sample size.
Traits.Our primary trait was WHRadjBMI, the ratio of waist and hip circumfer-
ences adjusted for age, age-squared, study-specific covariates if necessary andBMI.
For each cohort, residuals were calculated formen andwomen separately and then
transformed by the inverse standard normal function. Cohorts with related men
andwomenprovided inverse standardnormal transformed sex-combined residuals.
For each cohort, the same transformations were applied to other traits: (1) WHR
without adjustment for BMI (WHR); (2) waist circumference with (WCadjBMI)
and without adjustment for BMI; and (3) hip circumference with (HIPadjBMI)
and without adjustment for BMI.
European ancestrymeta-analysis for genome-wide SNP array data. Sample and
SNPquality control were undertakenwithin each cohort44 (SupplementaryTable 3).
The GWAS scaffold in each cohort was imputed up to CEU haplotypes from
HapMap resulting in ,2.5million SNPs. Each directly typed and imputed SNP
passing quality control was tested for association with each trait under an additive
model in a linear regression framework (SupplementaryTable 3). SNPpositions are
reported based on NCBI Build 36. For each cohort, sex-specific association sum-
mary statistics were corrected for residual population structure using the genomic
control inflation factor45 (medianlGC51.01, range50.99–1.08). SNPswere removed
before meta-analysis if they had a minor allele count#3, deviation from Hardy–
Weinberg equilibrium exact P, 1026, directly genotyped SNP call rate,95%, or
low imputationquality (below0.3 forMACH,0.4 for IMPUTE, and 0.8 for PLINK).
Association summary statistics for each trait were combined via inverse-variance
weighted fixed-effects meta-analysis and corrected for a second round of genomic
control to account for structure between cohorts (Extended Data Fig. 1 and Sup-
plementary Fig. 1).
European ancestrymeta-analysis forMetabochip data. Sample and SNP quality
control analyses were undertaken in each cohort (Supplementary Table 3). Each
SNP passing quality control was tested for association with each trait under an
additive model using linear regression. The Metabochip array11 is enriched, by
design, for loci associatedwith anthropometric andcardiometabolic traits, thus,we
based our correction on 4,425 SNPs selected for inclusion based on associations
with QT-interval that were not expected to be associated with anthropometric
traits (.500 kb fromvariantsonMetabochip46 for these traits). These study-specific
inflation factors had a median lGC 5 1.01(range 0.93–1.11), with only one study
exceeding 1.10. After removing SNPs for quality control as described in the pre-
vious section, association summary statistics were combined via inverse-variance
weighted fixed-effects meta-analysis and corrected for a second round of genomic
control on the basis of QT-interval SNPs to account for structure between cohorts.
European ancestry meta-analyses. Association summary statistics from the two
parts of the European ancestry armwere combined via inverse-variance weighted
fixed-effects meta-analysis using METAL47 with no further genomic control cor-
rection. Results were reported for SNPs with a sex-combined sample size$50,000.
The meta-analyses were repeated for men and women separately for each trait.
Analyseswere corrected for population structure within each sex. Themeta-analysis
of WHRadjBMI in men included up to 93,480 individuals, and in women up to
116,742 individuals.
Meta-analyses of studies of all ancestries. Sample and SNP quality control, tests
of association, genomic control correction (medianlGC5 1.01, range5 0.90–1.17,
with only one study exceeding 1.10), andmeta-analyseswere performedas described
above.Association summary statistics from theEuropean andnon-European ances-
try meta-analyses were combined via inverse-variance weighted fixed-effects meta-
analysis without further genomic control correction.
Heterogeneity. For each lead SNP, we tested for sex differences based on the sex-
specific beta estimates and standard errors, while accounting for potential correla-
tion between estimates as previously described10. Similarly, we tested for potential
differences in effects between European and non-European samples, comparing
the effects fromGWAS1Metabochip data for Europeans andMetabochip data for
non-Europeans, andwe tested for differences between population-based studies and
samples ascertainedondiabetes status, and cardiovascular disease, or both. Inassess-
ing effects of ascertainment overall, we compared effects in seven subsets of our
study sample using population-based studies (that is, those not ascertained on any
phenotype) as the referent population: (1) all studies ascertained on any pheno-
type, (2) T2D cases, (3) T2D controls, (4) T2D cases plus controls, (5) CAD cases,
(6) CAD controls and (7) CAD cases plus controls. We evaluated significance for
heterogeneity tests within each comparison using a Bonferroni-corrected P value
of 0.05/495 0.05/495 1.023 1023 as well as an FDR threshold48 of ,5% (Sup-
plementaryTable 28). Between-studyheterogeneity inallmeta-analyseswas assessed
using I2 statistics49.
Heritability and genetic and phenotypic correlations of waist traits. We cal-
culated the heritability and genetic correlations of several central obesity traits
using variance componentmodels50,51 in the FraminghamHeart Study (FHS) and
TwinGene study. In this approach, the phenotypic variance is decomposed into
additive genetic, non-additive genetic, and environmental sources of variation (includ-
ing model error), and for sets of traits, the covariances between traits. We report
narrow sense heritability (h2), the ratio of the additive genetic variance to the total
phenotypic variance. Sex-specific inverse normal trait residuals, adjusted for age
(and cohort in FHS), were used to estimate heritability separately in men and
women, using variance components analysis in SOLARv.4.2.7 (FHS)52 orMx1.703
(TwinGene)53. Additionally, the sex-specific residualswere used to conduct bivari-
ate quantitative variance component genetic analyses that calculate genetic and
environmental correlations between traits. The genetic correlations obtained are
estimates of the additive effects of shared genes, and a genetic correlation signifi-
cantly different fromzero suggests a direct influenceof the samegenes onmore than
one trait. Similarly, significant environmental correlations suggest shared environ-
mental effects.
We estimated sex-stratified correlations between all waist traits, as well as BMI,
height, andweight inTwinGene, FHS,KORA andEGCUT. InTwinGene and FHS,
age-adjusted Pearson correlations were used; in EGCUT and KORA, correlations
were adjusted for age and age-squared.
European ancestry approximate conditional analyses. To evaluate the evidence
for multiple association signals within identified loci, we performed approximate
conditional analyses of sex-combined, women-specific and men-specific data as
implemented in the GCTA software14,54. This approach makes use of association
summary statistics from the combined European ancestry meta-analysis and a
reference data set of individual-level genotype data to estimate LD between var-
iants and hence also the approximate correlation between allelic effect estimates
in a joint association model.
To evaluate robustness of the GCTA results, we performed analyses using two
referencedata sets: Prospective Investigationof theVasculature inUppsala Seniors
(PIVUS) consisting of 949 individuals from Uppsala County, Sweden, with both
GWAS andMetabochip genotype data; and Atherosclerosis Risk in Communities
(ARIC) consisting of 6,654 individuals of European descent from four communit-
ies in theUnitedStateswithGWASdata. BothGWASdata setswere imputedusing
data from phase II of the International HapMap Project55. Results shown use the
PIVUS reference data set because Metabochip genotypes are available (see a com-
parison in the Supplementary Note). Assuming that the LD correlations between
SNPsmore than 10megabases (Mb) away are zero, and using each referencedata set
in turn, we performed a genome-wide stepwise selection procedure to select asso-
ciated SNPs one-by-one at a P, 53 1028. For each locus at which multiple asso-
ciation signals were observed in the sex-combined, women-, and/or men-specific
data, the SNPs selected by GCTA as independently associated with WHRadjBMI
in any of the three meta-analyses are reported, with the SNP identified in the sex-
combined analysis taken bydefault whenproxies are identified in thewomen- and/
or men-specific analyses. For SNPs not selected by a particular joint conditional
analysis, but identified by either of the other two analyses, summary statistics were
calculated for association analysis of the SNP conditioned on the GCTA-selected
SNP(s).
Genetic risk score. We calculated a genetic risk score for each individual in the
population-basedKORAstudy (1,670men and 1,750women) using the 49 identified
variants, weighted by the allelic effect from the European ancestry meta-analyses of
WHRadjBMI. Sex-combined scoreswere computed on the basis of the sex-combined
meta-analysis. Sex-stratified scoreswere calculatedon the basis ofmen- andwomen-
specific meta-analyses, in which SNPs not achieving nominal significance in the
respective sex (P$ 0.05) were excluded. For each individual, the sex-combined
and sex-stratified risk scores were rounded to the nearest integer for plotting. Risk
scores were then tested for association withWHRadjBMI using linear regression.
Explained variance.We calculated the variance explained by a single SNP as:
2NMAFN 1{MAFð ÞN b
2
Var Yð Þ
in whichMAF is theminor allele frequency, b is the SNP effect estimate computed
bymeta-analysis, and Var(Y) is the variance of the phenotype Y as it went into the
study-specific association testing. To derive the total variance explained by a set of
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independent SNPs,we computed the sumof single-SNP explainedvariances under
the assumption of independent contributions.
To estimate the polygenic variance explained by all HapMap SNPs, we used the
all-SNP estimation approach implemented in GCTA and analysed individuals in
the ARIC and TwinGene cohorts, including the first 20 principal components as
fixed covariates. After removing one of each pair of individuals with estimated
genetic relatedness.0.025, 11,898 unrelated individuals withWHRadjBMI were
available.
Fine-mapping analyses.We considered each identified locus, defined as 500 kb
upstream and downstream of the lead SNP, and computed 99% credible intervals
using a Bayesian approach. On the basis of association summary statistics from
the European ancestry, non-European ancestry, or all ancestries sex-combined
meta-analyses, we calculated an approximate Bayes’ factor56 in favour of associa-
tion, given by:
BFj~
ffiffiffiffiffiffiffiffiffiffiffi
1{Rj
p
exp {
Rjb
2
j
2s2j
 !
in which bj is the allelic effect of the jth SNP, with corresponding standard error
sj, and Rj 5 0.04/(sj
2 1 0.04), which incorporates a N(0,0.22) prior for bj. This
prior gives high probability to small effect sizes, and only small probability to large
effect sizes.We then calculated the posterior probability that the jth SNP is causal
by:
Qj~
BFjP
k BFk
in which the summation in the denominator is over all SNPs passing quality
control across the locus. We compared the meta-analysis results and credible sets
of SNPs likely to contain the causal variant as described57. Assuming a single
causal variant at each locus, a 99% credible set of variants was then constructed by:
(1) ranking all SNPs according to their Bayes’ factor; and (2) combining ranked
SNPs until their cumulative posterior probability exceeded 0.99. For each locus,
we calculated the number of SNPs containedwithin the 99% credible sets, and the
length of the genomic interval covered by these SNPs.
Comparison of loci across traits. To determine whether the identified loci were
also associatedwith any of 22 cardio-metabolic traits, we obtained association data
frommeta-analysis consortiaDIAGRAM(T2D)58, CARDIoGRAM-C4D (CAD)59,
ICBP (diastolic and systolic blood pressure)60, GIANT (BMI, height)36,37, GLGC
(HDL, LDL, and triglycerides)61, MAGIC (fasting glucose, fasting insulin, fasting
insulin adjusted for BMI, and two-hour glucose)62–64, ADIPOGen (BMI-adjusted
adiponectin)65, CKDgen (urine albumin-to-creatinine ratio (UACR), estimated glo-
merular filtration rate (eGFR), and overall CKD)66,67, ReproGen (age at menarche,
age atmenopause)68,69, andGEFOS (bonemineral density)70; others provided asso-
ciation data for IgA nephropathy71 (also K.K., M.C., R.P.L. and A.G.G., unpub-
lished data) and for endometriosis (stage B cases only)72. Proxies (r2. 0.8 in CEU)
were used when an index SNP was unavailable.
Wealso searched theNHGRIGWAScatalogue forprevious SNP-trait associations
near our lead SNPs73.We supplemented the catalogue with additional genome-wide
significant SNP-trait associations from the literature13,70,74–80. We used PLINK to
identify SNPs within 500 kb of lead SNPs using 1000 Genomes Project pilot I
genotype data and LD (r2) values from CEU81,82; for rs7759742, HapMap release
22 CEU data81,83 were used. All SNPs within the specified regions were compared
with the NHGRI GWAS catalogue16.
Enrichment of concordant cross-trait associations and effects. To evaluate
whether the alleles associated with increased WHRadjBMI at the 49 identified
SNPs convey effects for any of the 22 cardiometabolic traits, we conducted meta-
regression analyses of the beta-estimates on thesemetabolic outcomes from other
consortia with the beta-estimates for WHRadjBMI in our data65.
On the basis of the association data across traits, we generated a matrix of
Z-scores by dividing the association betas for each of the 49 WHRadjBMI SNPs
for each of 22 traits by their respective standard errors. The traits did not include
WHRadjBMI or nephropathy in Chinese subjects, but did include HIPadjBMI
and WCadjBMI. Each Z-score was made positive if the original trait-increasing
allele also increased the look-up trait and negative if not. Missing associations with
were assigned a value of zero. We performed unsupervised hierarchical clustering
of the Z score matrix in R using the default settings of the ‘heatplot’ function from
the made4 library (version 1.20.0), agglomerating clusters using average linkage
and Pearson correlation metric distance. The rows and columns of matrix values
were each automatically scaled to range from 3 to23. Confidence in the hierarch-
ical clustering was assessed by bootstrap analysis (10,000 resamplings) using the R
package ‘pvclust’84.
Identification of candidate functional variants. The 1000 Genomes CEU pilot
datawere queried for SNPswithin 500 kb and in LD (r2. 0.7, an arbitrary thresh-
old)withany indexSNP.All identified variantswere thenannotatedbasedonRefSeq
transcripts usingAnnovar to identify potential nonsynonymous variants near iden-
tified association signals. The distance between each variant and the nearest tran-
scription start site were calculated using gene annotations fromGENCODE (v.12).
To investigate whether SNPs in LD with index SNPs are also in LD with com-
mon copy number variants (CNVs), we extracted waist trait association results for
a list of SNP proxies that are in high LD (r2. 0.8, CEU) with CNVs in European
populations as described previously7. Altogether 6,200 CNV-tagging SNPs were
used, which are estimated collectively to capture.40% of CNVs.1 kb in size.
eQTLs.We examined our lead SNPs in eQTL data sets from several sources (Sup-
plementary Note) for cis effects significant at P, 1025. We then checked if the
trait-associated SNP also had the strongest associationwith the expression level of
its corresponding transcript. If not, we identified a nearby SNP that had a stronger
association with expression (peak transcript SNP) of that transcript. To check
whether effects of the peak transcript SNP and waist trait-associated SNP over-
lapped, we conducted conditional analyses to estimate associations between the
waist-associated SNP and transcript level when the peak-transcript-associated
SNP was also included in the model, and vice versa. If the association for the
expression-associated SNPwas not significant (P. 0.05)when conditioned on the
waist-associated SNP,we concluded that thewaist-associatedSNP is likely to explain
a substantial proportion of the variance in gene transcript levels in the region.
For SNPs that passed these criteria in either women or men eQTL data sets from
deCODE,we investigated sexheterogeneity ingene transcript levels forwholeblood
(312 men, 435 women) and subcutaneous adipose tissue (252 men, 351 women)
based on the sex-specific beta estimates and standard errors, while accounting for
potential correlation between the sex-specific associations8.
Epigenomic regulatory element overlap with individual variants.We examined
overlap of regulatory elements with the 68 trait-associated variants and variants in
LD with them (r2. 0.7, 1000 Genomes phase 1 version 2 EUR85), totalling 1,547
variants.We obtained regulatory element data sets from the ENCODEConsortium24
and Roadmap Epigenomics Project25 corresponding to eight tissues selected based
ona current understanding ofWHRadjBMIpathways. The226 regulatory element
data sets included experimentally identified regions of open chromatin (DNase-
seq, FAIRE-seq), histone modification (H3K4me1, H3K27ac, H3K4me3, H3K9ac
andH3K4me2), and transcription factor binding (Supplementary Table 17).When
available, we downloadeddata processed during the ENCODE IntegrativeAnalysis24.
We processed Roadmap Epigenomics sequencing data with multiple biological
replicates using MACS2 (ref. 86) and the same Irreproducible Discovery Rate
pipeline used in the ENCODE Integrative Analysis. Roadmap Epigenomics data
with only a single replicate was processed using MACS2 alone.
Global enrichment of WHRadjBMI-associated loci in epigenomic data sets.
Weperformed permutation-based tests in a subset of 60 open chromatin (DNase-
seq) andhistonemodification (H3K27ac,H3K4me1,H3K4me3andH3K9ac) data
sets to identify global enrichment of theWHRadjBMI-associated loci.Wematched
the index SNP at each locus with 500 variants having no evidence of association
(P. 0.5, ,1.2million total variants) with a similar distance to the nearest gene
(611,655 bp), number of variants in LD (68 variants), andminor allele frequency.
Using these pools, we created 10,000 sets of control variants for each of the 49 loci
and identified variants in LD (r2. 0.7) and within 1Mb. For each SNP set, we
calculated the number of loci with at least one variant located in a regulatory region
under the assumption that one regulatory variant is responsible for each associ-
ation signal. We initially calculated an enrichment P value by finding the propor-
tion of control sets for which as many or more loci overlap a regulatory element
than the set of associated loci. For increased P value accuracy, we estimated the P
value assuming a sum of binomial distributions to represent the number of index
SNPs or their LD proxies that overlap a regulatory data set compared to the 500
matched control sets.
GRAIL. Gene Relationships Among Implicated Loci (GRAIL)19 is a text-mining
algorithmthat evaluates thedegreeof relatedness amonggeneswithin trait regions.
Using PubMed abstracts, a subset of genes enriched for relatedness and a set of
keywords that suggest putative pathways are identified. To avoid potential bias
from papers investigating candidate genes stimulated by GWAS, we restricted our
search to abstracts published before 2006.We tested for enrichment of connectiv-
ity in the independent SNPs that were significant in our study at P, 1025.
MAGENTA. To investigate whether pathways including predefined sets of genes
were enriched in the lower part of the gene P value distribution forWHRadjBMI,
we performed a pathway analysis usingMagenta 2.4 (ref. 20) and SNPs present in
both the Metabochip and GWAS meta-analyses. SNPs were assigned to a gene if
within 110 kb upstream or 40 kb downstream of the transcript’s boundaries. The
most significant SNP P value within this interval was adjusted for putative con-
founders (gene size, number of SNPs in a gene, LD pattern) using stepwise linear
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regression, creating a gene association score. If the same SNP was assigned to
multiple genes, only the genewith the lowest gene scorewas kept. TheHLA region
was removed from further analysesowing to its highLDstructure andgenedensity.
Each genewas then assignedpathway termsusingGeneOntology (GO), PANTHER,
Ingenuity and Kyoto Encyclopedia of Genes and Genomes (KEGG)87–90. Finally,
the genes were ranked based on their gene association score, and amodified gene-
set enrichment analysis usingMAGENTAwas performed. This analysis tested for
enrichment of gene association score ranks above a given rank cutoff (including
5% of all genes) in a gene-set belonging to a predefined pathway term, compared
to multiple, equally sized gene-sets that were randomly sampled from all genes in
the genome. Around 10,000–1,000,000 gene-set permutations were performed.
DEPICT. This method is described in detail elsewhere23,36. In brief, DEPICT uses
gene expression data derived froma panel of 77,840 expression arrays91, 5,984molec-
ular pathways (basedon 169,810 high-confidence experimentally derived protein–
protein interactions92), 2,473phenotypic gene sets (basedon211,882 gene-phenotype
pairs from the Mouse Genetics Initiative93), 737 reactome pathways94, 184 KEGG
pathways95, and 5,083GO terms19. DEPICTuses the expressiondata to reconstitute
the protein–protein interaction gene sets, mouse phenotype gene sets, reactome
pathway gene sets, KEGG pathway gene sets, and GO term gene sets. To avoid
biasing the identification of genes and pathways covered by SNPs on theMetabo-
chip, analyseswere restricted toGWAS cohort data and included 226WHRadjBMI
SNPs in 78 non-overlapping loci with sex-combined P, 1025.We used DEPICT
tomap genes to associatedWHRadjBMI loci, which then allowedus to (1) system-
atically identify themost likely causal gene(s) in a given associated region, (2) iden-
tify reconstituted gene sets thatwere enriched in genes fromassociated regions, and
(3) identify tissue and cell type annotations inwhich genes from associated regions
were highly expressed. Associated regionswere defined by all genes residingwithin
LD (r2. 0.5) distance of the WHRadjBMI-associated index SNPs. Overlapping
regions were merged, and SNPs that mapped near to or within the HLA region
were excluded. The 93 WHRadjBMI SNPs with P, 1025 (clumping thresholds:
HapMap release 27CEU r25 0.01, 500 kb) resulted in 78non-overlapping regions.
GWAS1Metabochip index SNPswere annotated withDEPICT-prioritized genes
if the DEPICT (GWAS-only) SNP was located within 500 kb. To mark related
gene sets, we first quantified significant gene sets’ pairwise overlap using a non-
probabilistic version of the reconstituted gene sets and the Jaccard indexmeasure.
Groups of gene setswithmutual Jaccard indices.0.25were subsequently referred
to asmeta gene sets and named by themost significant gene set in the group (Sup-
plementary Table 18 and Fig. 2a). In Fig. 2a, b, gene sets with similarities between
0.1 and 0.25 were connected by an edge that was scaled according to degree of
similarity. The Cytoscape tool was used to construct parts of Fig. 2 (ref. 96). In
Fig. 2c, we show the significance of all cell type annotations and annotations that
were categorized as ‘tissues’ at the outermost level of theMedical Subject Heading
ontology.
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Extended Data Figure 1 | Overall WHRadjBMI meta-analysis study design.
Data (dashed lines) and analyses (solid lines) related to the GWAS cohorts for
WHRadjBMI are coloured red and those related to the Metabochip (MC)
cohorts are coloured blue. The two genomic control (lGC) corrections
(within-study and among-studies) performed on associations from each data
set are represented by grey-outlined circles. The lGC corrections for the GWAS
meta-analysis were based on all SNPs and the lGC corrections for the
Metabochip meta-analysis were based on a null set of 4,319 SNPs previously
associated with QT interval. The joint meta-analysis of the GWAS and
Metabochip data sets is coloured purple. All SNP counts reflect a sample size
filter of n$ 50,000 subjects. Additional WHRadjBMI meta-analyses included
Metabochip data from up to 14,371 subjects of east Asian, south Asian or
African-American ancestry from eight cohorts. Counts for themeta-analyses of
waist circumference, hip circumference, and their BMI-adjusted counterparts
(WCadjBMI and HIPadjBMI) differ from those of WHRadjBMI because
some cohorts only had phenotype data available for one type of body
circumference measurement (see Supplementary Table 2).
RESEARCH ARTICLE
Macmillan Publishers Limited. All rights reserved©2015
Extended Data Figure 2 | Women- and men-specific effects, phenotypic
variances and genetic correlations. a, Figure showing effect beta estimates for
the 20WHRadjBMI SNPs showing significant evidence of sexual dimorphism.
Sex-specific effect betas and 95% confidence intervals for SNPs associated
with WHRadjBMI are shown as red circles and blue squares for women and
men, respectively. Sample sizes, comprising more than 73,576 men and 96,182
women, are listed in Table 1. The SNPs are classified into three categories:
(1) those showing a women-specific effect (‘women SSE’), namely a significant
effect in women and no effect in men (Pwomen, 53 10
28, Pmen$ 0.05),
(2) those showing a pronounced women effect (‘women CED’), namely a
significant effect in women and a less significant but directionally consistent
effect in men (Pwomen, 53 10
28, 53 1028 , Pmen# 0.05); and (3) those
showing a men-specific effect (‘men SSE’), namely a significant effect in men
and no effect in women (Pmen, 53 10
28, Pwomen$ 0.05). Within each of the
three categories, the loci were sorted by increasing P value of sex-based
heterogeneity in the effect betas. b, Figure showing standardized sex-specific
phenotypic variance components for six waist-related traits. Values are shown
in men (M) and women (W) from the Swedish Twin Registry (n5 11,875).
The ACEmodels are decomposed into additive genetic components (A) shown
in black, common environmental components (C) in grey, and non-shared
environmental components (E) in white. Components are shown for waist
circumference (WC), hip circumference (HIP), WHR, WCadjBMI,
HIPadjBMI and WHRadjBMI. When the ‘A’ component is different in men
and women with P, 0.05 for a given trait, its name is marked with an asterisk.
c, Genetic correlations of waist-related traits with height, adjusted for age
andBMI. Genetic correlations of three traitswithheightwere based on variance
component models in the Framingham Heart Study and TwinGene study
(see Methods).
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Extended Data Figure 3 | Cumulative genetic risk scores for WHRadjBMI
applied to the KORA study cohort. a, All subjects (n5 3,440,
Ptrend5 6.73 10
24). b, Only women (n5 1,750, Ptrend 5 1.03 10
211). c, Only
men (n5 1,690, Ptrend 5 0.02). Each genetic risk score illustrates the joint effect
of theWHRadjBMI-increasing alleles of the 49 identified variants fromTable 1
weighted by the relative effect sizes from the applicable sex-combined or
sex-specific meta-analysis. The mean WHRadjBMI residual and 95%
confidence interval is plotted for each genetic risk score category (red dots). The
histograms show each genetic risk score is normally distributed in KORA
(grey bars).
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Extended Data Figure 4 | Heat map of unsupervised hierarchical clustering
of the effects of 49 WHRadjBMI SNPs on 22 anthropometric and
metabolic traits and diseases. The matrix of Z-scores representing the set of
associations was scaled by row (locus name) and by column (trait) to range
from 23 to 3. Negative values (blue) indicate that theWHRadjBMI-increasing
allele was associated with decreased values of the trait and positive values (red)
indicate that this allele was associated with increased values of the trait.
Sample sizes for the associations are listed in Supplementary Table 8.
Dendrograms indicating the clustering relationships are shown to the left and
above the heat map. The WHRadjBMI-increasing alleles at the 49 lead SNPs
segregate into three major clusters comprised of alleles that associate with:
(1) largerWCadjBMI and smaller HIPadjBMI (n5 30 SNPs); (2) taller stature
and larger WCadjBMI (n5 8 SNPs); and (3) shorter stature and smaller
HIPadjBMI (n5 11 SNPs). The three visually identified SNP clusters could be
statistically distinguished with .90% confidence. Alleles of the first cluster
were predominantly associated with lower high density lipoprotein (HDL)
cholesterol and with higher triglycerides and fasting insulin adjusted for BMI
(FIadjBMI). BMD, bone mineral density; eGFRcrea, estimated glomerular
filtration rate based on creatinine; LDL cholesterol, low-density lipoprotein
cholesterol; UACR, urine albumin-to-creatinine ratio.
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Extended Data Figure 5 | Regulatory element overlap with WHRadjBMI-
associated loci. a, Five variants associated with WHRadjBMI and located
,77 kb upstream of the first CALCRL transcription start site overlap regions
with genomic evidence of regulatory activity in endothelial cells. b, Five
WHRadjBMI variants, including rs8817452, in a 1.1-kb region (box),250 kb
downstreamof the firstLEKR1 transcription start site overlap evidence of active
enhancer activity in adipose nuclei. Signal enrichment tracks are from the
ENCODE Integrative Analysis and the Roadmap Epigenomics track hubs on
the UCSC Genome Browser. Transcripts are from the GENCODE basic
annotation.
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ExtendedData Table 1 | WHRadjBMI loci withmultiple association signals in the sex-combined and/or sex-specific approximate conditional
meta-analyses
P values and b coefficients for the associationwithWHRadjBMI from the jointmodel in the approximate conditional analysis of combinedGWAS andMetabochip studies. SNPs selected by conditional analyses as
independently associatedwithWHRadjBMI in ameta-analysis (sex-combined, women- ormen-specific) have their respective summary statistics for these analysesmarked in black andbold. SNPsnot selected by
a particular conditional analysis as independently associated aremarked in grey and show the association analysis results for the SNP conditioned on the locus SNPs selected by GCTA. Sample sizes are from the
unconditioned meta-analysis.
*Locus and lead SNPs are defined by Table 1.
{The effect allele is the WHRadjBMI-increasing allele in the sex-combined analysis.
{Test for sex difference in conditional analysis based on the effect correlation estimate from primary analyses; values significant at the table-wise Bonferroni threshold of 0.05/2552 31023 aremarked in bold.
1SNPs selected by conditional analysis in the sex-combined analysis; proxies were selected by joint conditional analysis in the women- and/or men-specific analyses.
ISNP not present in the sex-specific meta-analyses due to sample size filter requiring n$50,000; sample size from GCTA.
"At NFE2L3-SNX10, different lead SNPs were identified in the European and all-ancestry analyses but LD is reported with respect to rs10245353.
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Extended Data Table 2 | Enrichments of 49 WHRadjBMI signal SNPs with metabolic and anthropometric traits
The 49 WHRadjBMI SNPs were tested for association with other traits by GWAS meta-analyses performed by other groups (see Methods). The maximum sample size available is shown overall or separately for
cases/controls.N indicates thenumber of the total SNPs forwhich theWHRadjBMI-increasing allele is associatedwith the trait in the concordantdirection (increased levels, except forHDL-C, adiponectin andBMI).
One-sidedbinomialP values testwhether this number is greater thanexpectedby chance (nullP50.5 andnullP50.025, respectively). The tests donot account for correlationbetweenWHRadjBMI and the tested
traits. P values representing significant column-wise enrichment (P,0.05/23 tests) are marked in bold.
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Extended Data Table 3 | Enrichment of 49 WHRadjBMI-associated loci in epigenomic data sets
Enrichment ofWHRadjBMI-associated loci in regulatory elements fromselectedWHRadjBMI-relevant tissues.P values arederivedusing a sumof binomial distributions (seeMethods).P valuesbelowaBonferroni-
corrected threshold for 60 tests of 8.3 31024 are indicated in bold font. The binomial-based P values are similar to P values generated from 10,000 permutation tests. Dashes indicate that data sets were not
available.
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Extended Data Table 4 | Candidate genes at new loci associated with additional waist and hip-related traits
Candidate genes for loci shown on Table 3 based on secondary analyses or literature review. Further details are provided in other Supplementary Tables and the Supplementary Note. Loci are shown in order of
chromosome and position.
*Gene transcript levels associated with SNP genotype (eQTL) in the indicated tissue(s).
{Genes in pathways identified as enriched by GRAIL analysis.
{Strongest candidate genes identified based on manual literature review.
1Traits associated at P,5 3 1028 in GWAS lookups or in the GWAS catalogue using the index SNP or a proxy in high LD (r2 . 0.7), and the genes(s) named in those reports.
INon-synonymous variants (nsSNPs) and copy number variants (CNVs) with tag SNPs in high LD with index SNP based on a 1000 Genomes CEU reference panel. DEPICT analysis was not performed for loci
associated with these traits.
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